| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
MFI-8 targets mitofusin-1 (MFN1) and mitofusin-2 (MFN2), which are key proteins involved in mitochondrial fusion. By inhibiting these mitofusins, MFI-8 disrupts the fusion process, leading to a shift towards mitochondrial fission. This results in a significant reduction in the mitochondrial aspect ratio (a measure of mitochondrial elongation). The compound binds to the HR2 domain of MFN2.
|
|---|---|
| ln Vitro |
MFI8 (20 μM; 6 h) inhibits mitofusin-mediated mitochondrial activity, hence inducing mitochondrial fission, and drastically lowers mitochondrial aspect ratio (EC50 = 4.8 μM) [1]. MFI8 satisfies the requirements of the pharmacophore model and is a functional group that has the ability to bind to mitochondrial fusins. MFI8 alters mitochondrial function and MFN structure and complex by binding to the HR2 domain of MFN2 [1]. MFI8 (0 – 20 μM; 6 hours) exhibits concentration-dependent increases in caspase-3/7 activity, cytochrome c release, and a decrease in membrane potential that is dependent on mitogens. In addition, MFI8 when combined with BV6 SMAC (last source caspase activator) mimics can cause damage to DNA and cell death [1].
In vitro, MFI-8 (20 μM; 6 h) inhibits mitofusin-mediated mitochondrial activity, inducing mitochondrial fission. It drastically lowers the mitochondrial aspect ratio with an EC50 of 4.8 μM. At 20 μM, it significantly reduces the mitochondrial aspect ratio. The compound meets the requirements of the pharmacophore model and has functional groups with binding capacity to mitofusins. |
| ln Vivo |
Specific in vivo activity data for MFI-8 are not provided in the available sources. As a compound that regulates mitochondrial fission, it could be used to study aging and disorders with impaired mitochondrial dynamics. However, no specific in vivo studies or efficacy data are described in the references cited.
|
| Enzyme Assay |
A cell-free assay for MFI-8 would involve measuring its binding to the HR2 domain of MFN2 or its ability to inhibit mitofusin-mediated membrane fusion in vitro. These assays would typically use purified proteins and assess the compound's ability to disrupt protein-protein interactions or membrane fusion activity. Specific protocols are not detailed in the available sources.
|
| Cell Assay |
Cellular assays for MFI-8 typically involve assessing its effects on mitochondrial morphology. Cells are treated with the compound, and mitochondria are labeled with a fluorescent dye or a mitochondrial-targeted fluorescent protein. The mitochondrial aspect ratio is then measured using image analysis software. The compound's ability to induce mitochondrial fission is quantified by measuring the decrease in aspect ratio.
|
| Animal Protocol |
In vivo animal experiments for MFI-8 are not described in the available sources. As a compound that regulates mitochondrial fission, it could be evaluated in animal models of aging or mitochondrial diseases. However, no specific protocols or data are provided.
|
| ADME/Pharmacokinetics |
MFI-8 has a molecular formula of C16H18ClNO and a molecular weight of 275.77 g/mol. Its IUPAC name is 4-chloro-2-(1-((2,3-dimethylphenyl)amino)ethyl)phenol. Specific pharmacokinetic parameters, such as half-life and bioavailability, are not provided in the available sources. As a research compound, it is intended for preclinical studies. For storage, the powder should be kept at -20°C.
|
| Toxicity/Toxicokinetics |
Toxicity data for MFI-8 are not provided in the available sources. As a research compound, it is intended for research use only and is not for human consumption. Standard laboratory safety precautions should be observed when handling this compound.
|
| References | |
| Additional Infomation |
MFI-8 (CAS: 694488-83-0) is a small molecule inhibitor of mitofusin-1 and -2. It is also known as MFI8. The compound promotes mitochondrial fission with an EC50 of 4.8 μM. It is used in research on mitochondrial dynamics and aging. It is not an approved drug and is strictly for research purposes.
|
| Molecular Formula |
C16H18CLNO
|
|---|---|
| Molecular Weight |
275.773223400116
|
| Exact Mass |
275.107
|
| CAS # |
694488-83-0
|
| PubChem CID |
2947511
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.8
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
19
|
| Complexity |
286
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1(O)=CC=C(Cl)C=C1C(NC1=CC=CC(C)=C1C)C
|
| InChi Key |
DYILWFVSLLZIIR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H18ClNO/c1-10-5-4-6-15(11(10)2)18-12(3)14-9-13(17)7-8-16(14)19/h4-9,12,18-19H,1-3H3
|
| Chemical Name |
4-chloro-2-[1-(2,3-dimethylanilino)ethyl]phenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~362.62 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6262 mL | 18.1311 mL | 36.2621 mL | |
| 5 mM | 0.7252 mL | 3.6262 mL | 7.2524 mL | |
| 10 mM | 0.3626 mL | 1.8131 mL | 3.6262 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
